NCT02670187View on ClinicalTrials.gov

Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

September 30, 2017

Conditions
Healthy
Interventions
BIOLOGICAL

GLS-5300

Trial Locations (1)

20910

Walter Reed Institute of Research, Silver Spring

Sponsors

Collaborators (1)

Inovio Pharmaceuticals
All Listed Sponsors
collaborator

Inovio Pharmaceuticals

INDUSTRY

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

GeneOne Life Science, Inc.

INDUSTRY

NCT02670187 - Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers | Biotech Hunter | Biotech Hunter